Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

References

• World Health Organisation WHO. Global tuberculosis report. 2018.
   Google Scholar
• Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22(6):1154–1158.
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173–1180.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Xia M, Zhang GL, et al. PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures. Mucosal Immunol. 2018;11(2):486–495.
   PubMed Web of Science ®Google Scholar
• Bull NC, Stylianou E, Kaveh DA, et al. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1(+) KLRG1(-) CD4(+) T cells. Mucosal Immunol. 2019;12(2):555–564.
   PubMed Web of Science ®Google Scholar
• Ganesan S, Comstock AT, Sajjan US. Barrier function of airway tract epithelium. Tissue Barriers. 2013;1(4):e24997.
   PubMedGoogle Scholar
• McGhee JR, Fujihashi K. Inside the mucosal immune system. PLoS Biol. 2012;10(9):e1001397.
   PubMed Web of Science ®Google Scholar
• Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol. 1987;7(4):265–276.
   PubMed Web of Science ®Google Scholar
• Kraehenbuhl JP, Neutra MR. Epithelial M cells: differentiation and function. Annu Rev Cell Dev Biol. 2000;16:301–332.
   PubMed Web of Science ®Google Scholar
• Randall TD. Pulmonary dendritic cells: thinking globally, acting locally. J Exp Med. 2010;207(3):451–454.
   PubMed Web of Science ®Google Scholar
• Heritage PL, Underdown BJ, Arsenault AL, et al. Comparison of murine nasal-associated lymphoid tissue and Peyer’s patches. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1256–1262.
   PubMed Web of Science ®Google Scholar
• Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. 2004;10(9):927–934.
   PubMed Web of Science ®Google Scholar
• Kahnert A, Hopken UE, Stein M, et al. Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis. 2007;195(1):46–54.
   PubMed Web of Science ®Google Scholar
• Kashino SS, Vallerskog T, Martens G, et al. Initiation of acquired immunity in the lungs of mice lacking lymph nodes after infection with aerosolized Mycobacterium tuberculosis. Am J Pathol. 2010;176(1):198–204.
   PubMed Web of Science ®Google Scholar
• Hwang JY, Randall TD, Silva-Sanchez A. Inducible bronchus-associated lymphoid tissue: taming inflammation in the lung. Front Immunol. 2016;7:258.
   PubMed Web of Science ®Google Scholar
• Foreman TW, Mehra S, LoBato DN, et al. CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. Proc Natl Acad Sci U S A. 2016;113(38):E5636–5644.
   PubMed Web of Science ®Google Scholar
• Kaushal D, Foreman TW, Gautam US, et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat Commun. 2015;6:8533.
   PubMed Web of Science ®Google Scholar
• Silver RF, Myers AJ, Jarvela J, et al. Diversity of human and macaque airway immune cells at baseline and during tuberculosis infection. Am J Respir Cell Mol Biol. 2016;55(6):899–908.
   PubMed Web of Science ®Google Scholar
• Capuano SV 3rd, Croix DA, Pawar S, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun. 2003;71(10):5831–5844.
   PubMed Web of Science ®Google Scholar
• Barker L, Hessel L, Walker B. Rational approach to selection and clinical development of TB vaccine candidates. Tuberculosis (Edinb). 2012;92(Suppl 1):S25–29.
   PubMedGoogle Scholar
• Schaible UE, Linnemann L, Redinger N, et al. Strategies to improve vaccine efficacy against tuberculosis by targeting innate immunity. Front Immunol. 2017;8:1755.
   PubMed Web of Science ®Google Scholar
• Kaufmann E, Sanz J, Dunn JL, et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell. 2018;172(1–2):176–190 e119.
   PubMed Web of Science ®Google Scholar
• Ardain A, Domingo-Gonzalez R, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019;570:528–532.
   PubMed Web of Science ®Google Scholar
• Joosten SA, Ottenhoff THM, Lewinsohn DM, et al. Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. Vaccine. 2019;37(23):3022–3030.
   PubMed Web of Science ®Google Scholar
• Vorkas CK, Wipperman MF, Li K, et al. Mucosal-associated invariant and gammadelta T cell subsets respond to initial Mycobacterium tuberculosis infection. JCI Insight. 2018;3:19.
   Web of Science ®Google Scholar
• Paquin-Proulx D, Costa PR, Terrassani Silveira CG, et al. Latent Mycobacterium tuberculosis infection is associated with a higher frequency of mucosal-associated invariant T and Invariant natural killer t cells. Front Immunol. 2018;9:1394.
   PubMedGoogle Scholar
• Malka-Ruimy C, Ben Youssef G, Lambert M, et al. Mucosal-associated invariant T cell levels are reduced in the peripheral blood and lungs of children with active pulmonary tuberculosis. Front Immunol. 2019;10:206.
   PubMed Web of Science ®Google Scholar
• Greene JM, Dash P, Roy S, et al. MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. Mucosal Immunol. 2017;10(3):802–813.
   PubMed Web of Science ®Google Scholar
• Boyaka PN. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J Immunol. 2017;199(1):9–16.
   PubMed Web of Science ®Google Scholar
• Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:185.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Tjarnlund A, Ivanji J, et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine. 2005;23(20):2565–2572.
   PubMed Web of Science ®Google Scholar
• Tjarnlund A, Rodriguez A, Cardona PJ, et al. Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice. Int Immunol. 2006;18(5):807–816.
   PubMed Web of Science ®Google Scholar
• Jacobs AJ, Mongkolsapaya J, Screaton GR, et al. Antibodies and tuberculosis. Tuberculosis (Edinb). 2016;101:102–113.
   PubMed Web of Science ®Google Scholar
• Williams A, Reljic R, Naylor I, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 2004;111(3):328–333.
   PubMed Web of Science ®Google Scholar
• Lopez Y, Yero D, Falero-Diaz G, et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol. 2009;299(6):447–452.
   PubMed Web of Science ®Google Scholar
• Balu S, Reljic R, Lewis MJ, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011;186(5):3113–3119.
   PubMed Web of Science ®Google Scholar
• Allie SR, Bradley JE, Mudunuru U, et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat Immunol. 2019;20(1):97–108.
   PubMed Web of Science ®Google Scholar
• Lin PL, Rutledge T, Green AM, et al. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retroviruses. 2012;28(12):1693–1702.
   PubMed Web of Science ®Google Scholar
• Cooper AM, Dalton DK, Stewart TA, et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med. 1993;178(6):2243–2247.
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993;178(6):2249–2254.
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Triebold KJ, et al. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A. 1992;89(24):12013–12017.
   PubMed Web of Science ®Google Scholar
• Mittrucker HW, Steinhoff U, Kohler A, et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A. 2007;104(30):12434–12439.
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Tameris M, Mansoor N, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010;40(1):279–290.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272(5258):54–60.
   PubMed Web of Science ®Google Scholar
• Reiner SL, Sallusto F, Lanzavecchia A. Division of labor with a workforce of one: challenges in specifying effector and memory T cell fate. Science. 2007;317(5838):622–625.
   PubMed Web of Science ®Google Scholar
• Copland A, Diogo GR, Hart P, et al. Mucosal delivery of fusion proteins with bacillus subtilis spores enhances protection against tuberculosis by bacillus calmette-guerin. Front Immunol. 2018;9:346.
   PubMed Web of Science ®Google Scholar
• Gebhardt T, Wakim LM, Eidsmo L, et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10(5):524–530.
   PubMed Web of Science ®Google Scholar
• Masopust D, Choo D, Vezys V, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med. 2010;207(3):553–564.
   PubMed Web of Science ®Google Scholar
• Galkina E, Thatte J, Dabak V, et al. Preferential migration of effector CD8+ T cells into the interstitium of the normal lung. J Clin Invest. 2005;115(12):3473–3483.
   PubMed Web of Science ®Google Scholar
• Teijaro JR, Turner D, Pham Q, et al. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol. 2011;187(11):5510–5514.
   PubMed Web of Science ®Google Scholar
• Anderson KG, Sung H, Skon CN, et al. Cutting edge: intravascular staining redefines lung CD8 T cell responses. J Immunol. 2012;189(6):2702–2706.
   PubMed Web of Science ®Google Scholar
• Anderson KG, Mayer-Barber K, Sung H, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc. 2014;9(1):209–222.
   PubMed Web of Science ®Google Scholar
• Turner DL, Bickham KL, Thome JJ, et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 2014;7(3):501–510.
   PubMed Web of Science ®Google Scholar
• Sakai S, Kauffman KD, Schenkel JM, et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J Immunol. 2014;192(7):2965–2969.
   PubMed Web of Science ®Google Scholar
• Slutter B, Van Braeckel-Budimir N, Abboud G, et al. Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity. Sci Immunol. 2017;2(7):eaag2031.
   PubMed Web of Science ®Google Scholar
• Woodworth JS, Christensen D, Cassidy JP, et al. Mucosal boosting of H56: CAF01immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection. Mucosal Immunol. 2019;12(3):816–826.
   PubMed Web of Science ®Google Scholar
• Florido M, Muflihah H, Lin LCW, et al. Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4(+) memory T cells that are associated with protection against tuberculosis. Mucosal Immunol. 2018;11(6):1743–1752.
   PubMed Web of Science ®Google Scholar
• Perdomo C, Zedler U, Kuhl AA, et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. MBio. 2016;7(6):e01686-16.
   PubMed Web of Science ®Google Scholar
• Aguilo N, Alvarez-Arguedas S, Uranga S, et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism. J Infect Dis. 2016;213(5):831–839.
   PubMed Web of Science ®Google Scholar
• Dijkman K, Sombroek CC, Vervenne RAW, et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat Med. 2019;25(2):255–262.
   PubMed Web of Science ®Google Scholar
• Ballester M, Nembrini C, Dhar N, et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011;29(40):6959–6966.
   PubMed Web of Science ®Google Scholar
• Griffiths KL, Stylianou E, Poyntz HC, et al. Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice. PLoS One. 2013;8(10):e78312.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Jiao H, Domingo-Gonzalez R, et al. Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice. J Leukoc Biol. 2017;101(6):1373–1381.
   PubMed Web of Science ®Google Scholar
• Gopal R, Rangel-Moreno J, Slight S, et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 2013;6(5):972–984.
   PubMed Web of Science ®Google Scholar
• WHO. Position paper on polio vaccines. 2016.
   Google Scholar
• Kabir S, Alexander TS. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clin Vaccine Immunol. 2014;21(9):1195–1205.
   PubMedGoogle Scholar
• England PH. Influenza vaccine effectiveness (VE) in adults and children in primary care in the United Kingdom (UK): provisional end-of-season results 2017-18. 2018.
   Google Scholar
• Moron VG, Rueda P, Sedlik C, et al. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol. 2003;171(5):2242–2250.
   PubMed Web of Science ®Google Scholar
• Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin. 2005;1(1):30–36.
   PubMed Web of Science ®Google Scholar
• Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med. 2015;372(16):1519–1529.
   PubMed Web of Science ®Google Scholar
• Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet. 2000;355(9206):798–803.
   PubMed Web of Science ®Google Scholar
• Cosgrove CA, Castello-Branco LR, Hussell T, et al. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect Immun. 2006;74(4):2449–2452.
   PubMed Web of Science ®Google Scholar
• Benevolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, et al. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis – review. Mem Inst Oswaldo Cruz. 2005;100(5):459–465.
   PubMed Web of Science ®Google Scholar
• Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116–131.
   PubMed Web of Science ®Google Scholar
• Monteiro-Maia R, Pinho RT. Oral bacillus Calmette-Guerin vaccine against tuberculosis: why not? Mem Inst Oswaldo Cruz. 2014;109(6):838–845.
   PubMed Web of Science ®Google Scholar
• Cohn ML, Davis CL, Middlebrook G. Airborne immunization against tuberculosis. Science. 1958;128(3334):1282–1283.
   PubMed Web of Science ®Google Scholar
• Derrick SC, Kolibab K, Yang A, et al. Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice. Clin Vaccine Immunol. 2014;21(10):1443–1451.
   PubMedGoogle Scholar
• Aguilo N, Toledo AM, Lopez-Roman EM, et al. Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination. Clin Vaccine Immunol. 2014;21(4):594–597.
   PubMed Web of Science ®Google Scholar
• Lagranderie M, Ravisse P, Marchal G, et al. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber Lung Dis. 1993;74(1):38–46.
   PubMedGoogle Scholar
• Barclay WR, Busey WM, Dalgard DW, et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am Rev Respir Dis. 1973;107(3):351–358.
   PubMedGoogle Scholar
• Garcia-Contreras L, Wong YL, Muttil P, et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A. 2008;105(12):4656–4660.
   PubMed Web of Science ®Google Scholar
• Sharpe S, White A, Sarfas C, et al. Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations. Tuberculosis (Edinb). 2016;101:174–190.
   PubMed Web of Science ®Google Scholar
• Verreck FAW, Tchilian EZ, Vervenne RAW, et al. Variable BCG efficacy in rhesus populations: pulmonary BCG provides protection where standard intra-dermal vaccination fails. Tuberculosis (Edinb). 2017;104:46–57.
   PubMed Web of Science ®Google Scholar
• Dean GS, Clifford D, Whelan AO, et al. Protection induced by simultaneous subcutaneous and endobronchial vaccination with BCG/BCG and BCG/adenovirus expressing antigen 85A against mycobacterium bovis in cattle. PLoS One. 2015;10(11):e0142270.
   PubMed Web of Science ®Google Scholar
• Rosenthal SR, McEnery JT, Raisys N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J Asthma Res. 1968;5(4):309–323.
   PubMedGoogle Scholar
• Arbues A, Aguilo JI, Gonzalo-Asensio J, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013;31(42):4867–4873.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant bacille calmette-guerin vaccine vpm1002: ready for clinical efficacy testing. Front Immunol. 2017;8:1147.
   PubMed Web of Science ®Google Scholar
• Moliva JI, Hossfeld AP, Canan CH, et al. Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8(+) T-cell-dependent manner. Mucosal Immunol. 2018;11(3):968–978.
   PubMed Web of Science ®Google Scholar
• Moliva JI, Hossfeld AP, Sidiki S, et al. Selective delipidation of Mycobacterium bovis BCG enables direct pulmonary vaccination and enhances protection against Mycobacterium tuberculosis. Mucosal Immunol. 2019;12(3):805–815.
   PubMed Web of Science ®Google Scholar
• Nemes E, Hesseling AC, Tameris M, et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed bacille calmette-guerin for infants of human immunodeficiency virus-infected mothers: a phase 2 randomized, controlled trial. Clin Infect Dis. 2018;66(4):554–563.
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.
   PubMed Web of Science ®Google Scholar
• Ndiaye BP, Thienemann F, Ota M, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015;3(3):190–200.
   PubMed Web of Science ®Google Scholar
• Tameris M, Geldenhuys H, Luabeya AK, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS One. 2014;9(2):e87340.
   PubMed Web of Science ®Google Scholar
• Satti I, Meyer J, Harris SA, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(10):939–946.
   PubMed Web of Science ®Google Scholar
• Manjaly Thomas ZR, Satti I, Marshall JL, et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: a phase I randomised controlled trial. PLoS Med. 2019;16(4):e1002790.
   PubMed Web of Science ®Google Scholar
• Halle S, Dujardin HC, Bakocevic N, et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med. 2009;206(12):2593–2601.
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol. 2005;18(2):283–291.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616–629.
   PubMed Web of Science ®Google Scholar
• Sheehan S, Harris SA, Satti I, et al. A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults. PLoS One. 2015;10(11):e0141687.
   PubMed Web of Science ®Google Scholar
• Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med. 2013;5(205):205ra134.
   PubMed Web of Science ®Google Scholar
• Tameris M, Hokey DA, Nduba V, et al. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015;33(25):2944–2954.
   PubMed Web of Science ®Google Scholar
• Jeyanathan M, Shao Z, Yu X, et al. AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates. PLoS One. 2015;10(8):e0135009.
   PubMed Web of Science ®Google Scholar
• Darrah PA, DiFazio RM, Maiello P, et al. Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques. NPJ Vaccines. 2019;4:21.
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer KJ, Bowyer G, et al. Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP. J Infect Dis. 2016;214(5):772–781.
   PubMed Web of Science ®Google Scholar
• Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017;2(21):e96381.
   Web of Science ®Google Scholar
• Stylianou E, Griffiths KL, Poyntz HC, et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine. 2015;33(48):6800–6808.
   PubMed Web of Science ®Google Scholar
• [cited 2019 May 31]. https://www.kofam.ch/en/snctp-portal/search/54823/study/42879
   Google Scholar
• Jeyanathan M, Thanthrige-Don N, Afkhami S, et al. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Mucosal Immunol. 2015;8(6):1373–1387.
   PubMed Web of Science ®Google Scholar
• Stylianou E, Harrington-Kandt R, Beglov J, et al. Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infect Immun. 2018;86(7):e00014–18.
   PubMed Web of Science ®Google Scholar
• Aoshi T. Modes of action for mucosal vaccine adjuvants. Viral Immunol. 2017;30(6):463–470.
   PubMed Web of Science ®Google Scholar
• Madhun AS, Haaheim LR, Nostbakken JK, et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine. 2011;29(31):4973–4982.
   PubMed Web of Science ®Google Scholar
• Van Maele L, Fougeron D, Janot L, et al. Airway structural cells regulate TLR5-mediated mucosal adjuvant activity. Mucosal Immunol. 2014;7(3):489–500.
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Cate TR, et al. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009;27(39):5344–5348.
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004;350(9):896–903.
   PubMed Web of Science ®Google Scholar
• Overton ET, Goepfert PA, Cunningham P, et al. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine. 2014;32(42):5490–5495.
   PubMed Web of Science ®Google Scholar
• Brekke K, Lind A, Holm-Hansen C, et al. Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial. PLoS One. 2014;9(11):e112556.
   PubMed Web of Science ®Google Scholar
• Lambkin-Williams R, Gelder C, Broughton R, et al. An intranasal proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. serum IgG & mucosal IgA are important correlates of protection against illness associated with infection. PLoS One. 2016;11(12):e0163089.
   PubMed Web of Science ®Google Scholar
• Rosada RS, de la Torre LG, Frantz FG, et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol. 2008;9:38.
   PubMed Web of Science ®Google Scholar
• Stylianou E, Diogo GR, Pepponi I, et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur J Immunol. 2014;44(2):440–449.
   PubMed Web of Science ®Google Scholar
• Wong EA, Agger EM, Andersen P, et al. Vaccination route has an impact on level of protection of non-human primates from tuberculosis. J Immunol. 2016;196((1 Supplement)):146.121.
   Google Scholar
• Goonetilleke NP, McShane H, Hannan CM, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol. 2003;171(3):1602–1609.
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, et al. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun. 2006;74(8):4634–4643.
   PubMed Web of Science ®Google Scholar
• Xing Z, McFarland CT, Sallenave JM, et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One. 2009;4(6):e5856.
   PubMed Web of Science ®Google Scholar
• Whelan A, Court P, Xing Z, et al. Immunogenicity comparison of the intradermal or endobronchial boosting of BCG vaccinates with Ad5-85A. Vaccine. 2012;30(44):6294–6300.
   PubMed Web of Science ®Google Scholar
• Uranga S, Marinova D, Martin C, et al. Protective efficacy and pulmonary immune response following subcutaneous and intranasal BCG administration in mice. J Vis Exp. 2016;115:e54440.
   Google Scholar
• Guerra-Maupome M, Vang DX, McGill JL. Aerosol vaccination with Bacille Calmette-Guerin induces a trained innate immune phenotype in calves. PLoS One. 2019;14(2):e0212751.
   PubMed Web of Science ®Google Scholar
• White AD, Sarfas C, West K, et al. Evaluation of the immunogenicity of mycobacterium bovis BCG delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol. 2015;22(9):992–1003.
   PubMed Web of Science ®Google Scholar
• Kaushal D, Schroeder BG, Tyagi S, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A. 2002;99(12):8330–8335.
   PubMed Web of Science ®Google Scholar
• Gupta T, LaGatta M, Helms S, et al. Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs. Tuberculosis (Edinb). 2018;113:179–188.
   PubMed Web of Science ®Google Scholar
• Hall LJ, Clare S, Pickard D, et al. Characterisation of a live salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine. 2009;27(49):6894–6904.
   PubMed Web of Science ®Google Scholar
• Hart P, Copland A, Diogo GR, et al. Nanoparticle-fusion protein complexes protect against Mycobacterium tuberculosis infection. Mol Ther. 2018;26(3):822–833.
   PubMed Web of Science ®Google Scholar
• Wilkhu JS, McNeil SE, Anderson DE, et al. Development of a solid dosage platform for the oral delivery of bilayer vesicles. Eur J Pharm Sci. 2017;108:71–77.
   PubMed Web of Science ®Google Scholar
• Tyne AS, Chan JG, Shanahan ER, et al. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine. 2013;31(40):4322–4329.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr., Bauch CT, Bresnahan BW, et al. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. J Infect Dis. 2011;204(Suppl 1):S124–132.
   PubMed Web of Science ®Google Scholar
• Kiyono H, Fukuyama S. NALT- versus Peyer’s-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4(9):699–710.
   PubMed Web of Science ®Google Scholar
• Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1(4):315–320.
   PubMedGoogle Scholar
• Torrelles JB, Schlesinger LS. Integrating lung physiology, immunology, and tuberculosis. Trends Microbiol. 2017;25(8):688–697.
   PubMed Web of Science ®Google Scholar
• Fennelly KP, Martyny JW, Fulton KE, et al. Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir Crit Care Med. 2004;169(5):604–609.
   PubMed Web of Science ®Google Scholar
• Khanal A, Sharma R, Corcoran TE, et al. Surfactant driven post-deposition spreading of aerosols on complex aqueous subphases. 1: high deposition flux representative of aerosol delivery to large airways. J Aerosol Med Pulm Drug Deliv. 2015;28(5):382–393.
   PubMed Web of Science ®Google Scholar
• Sidler-Moix AL, Dolci U, Berger-Gryllaki M, et al. Albuterol delivery in an in vitro pediatric ventilator lung model: comparison of jet, ultrasonic, and mesh nebulizers. Pediatr Crit Care Med. 2013;14(2):e98–102.
   PubMed Web of Science ®Google Scholar
• White AD, Sibley L, Dennis MJ, et al. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol. 2013;20(5):663–672.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Colgate ER, Mychaleckyj JC, et al. The “performance of rotavirus and oral polio vaccines in developing countries” (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. Am J Trop Med Hyg. 2015;92(4):744–751.
   PubMed Web of Science ®Google Scholar
• Lex JR, Azizi A. Microbiota, a forgotten relic of vaccination. Expert Rev Vaccines. 2017;16(12):1171–1173.
   PubMed Web of Science ®Google Scholar
• Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125(2):e199–207.
   PubMed Web of Science ®Google Scholar
• Buttery JP, Lambert SB, Grimwood K, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30(1 Suppl):S25–29.
   PubMed Web of Science ®Google Scholar
• Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–614.
   PubMed Web of Science ®Google Scholar
• Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615–623.
   PubMed Web of Science ®Google Scholar
• Huda MN, Lewis Z, Kalanetra KM, et al. Stool microbiota and vaccine responses of infants. Pediatrics. 2014;134(2):e362–372.
   PubMed Web of Science ®Google Scholar
• Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15(1):55–63.
   PubMed Web of Science ®Google Scholar
• Elias D, Britton S, Aseffa A, et al. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. Vaccine. 2008;26(31):3897–3902.
   PubMed Web of Science ®Google Scholar
• Resende Co T, Hirsch CS, Toossi Z, et al. Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy. Clin Exp Immunol. 2007;147(1):45–52.
   PubMed Web of Science ®Google Scholar
• O’Shea MK, Fletcher TE, Muller J, et al. Human hookworm infection enhances mycobacterial growth inhibition and associates with reduced risk of tuberculosis infection. Front Immunol. 2018;9:2893.
   PubMed Web of Science ®Google Scholar
• Perry S, Hussain R, Parsonnet J. The impact of mucosal infections on acquisition and progression of tuberculosis. Mucosal Immunol. 2011;4(3):246–251.
   PubMed Web of Science ®Google Scholar
• Dumas A, Corral D, Colom A, et al. The host microbiota contributes to early protection against lung colonization by Mycobacterium tuberculosis. Front Immunol. 2018;9:2656.
   PubMed Web of Science ®Google Scholar
• Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15(5):259–270.
   PubMed Web of Science ®Google Scholar
• Hong BY, Paulson JN, Stine OC, et al. Meta-analysis of the lung microbiota in pulmonary tuberculosis. Tuberculosis (Edinb). 2018;109:102–108.
   PubMed Web of Science ®Google Scholar